Home / Market News / $NVCR
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

NovoCure Limited 12-Month Price Target Reduced to $21.33

Nov 1, 2026, 8:03 AM UTC · Primary ticker $NVCR

NovoCure Limited's average 12-month price target has been reduced by analysts, though the consensus rating remains a 'Buy.' This indicates a tempered outlook on future growth while still suggesting significant upside potential from current levels.

Six covering analysts have lowered their average 12-month price target for NovoCure Limited from $25.71 to $21.33. This reduction suggests a more conservative outlook on the company's near-term growth prospects or market conditions. Despite the lower target, the consensus rating remains a 'Buy,' implying that analysts still see significant value and potential upside (approximately 62%) from the current stock price. For traders, this presents a mixed signal: a lower price target could exert downward pressure in the short term, but the maintained 'Buy' rating and substantial implied upside might attract long-term investors. The key risk is whether the company can meet or exceed these revised expectations to justify the 'Buy' rating.

$NVCR neutral Price target reduced but 'Buy' rating maintained
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.